The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column focuses on the commercially available and investigational agents used to treat malignant diseases and reviews issues related to the preparation, dispensing, and administration of cancer chemotherapy.
Get full access to this article
View all access options for this article.
References
1.
ThomasJ.P., ArzoomanianR., AlbertiD.A phase I and pharmacodynamic study of the proteasome inhibitor PS-341 in combination with doxorubicin [Abstract 368].Proc Am Soc Clin Oncol.2002; 21.
2.
RyanD.P., EderJ.P., WinkelmannJ.Pharmacokinetic and pharmacodynamic phase I study of PS-341 and gemcitabine in patients with advanced solid tumors [(Abstract 379].Proc Am Soc Clin Oncol.2002; 21.
3.
RichardsonP.G., BarlogieB., BerensonJ.Phase II study of bortezomib in relapsed, refractory multiple myeloma.N Engl J Med.2003; 348(26): 2609–17.
4.
ShahM.H., MartinE., EllisonC.A phase II study of proteasome inhibitor PS-341 in metastatic neuroendocrine tumors [Abstract 111].Proc Am Soc Clin Oncol.2002; 21.
5.
IqbalS., LenzH.J., GroshenS., WeiY.Phase I study of PS-341 in combination with 5-FU/LV in solid tumors [Abstract 370].Proc Am Soc Clin Oncol.2002; 21.
6.
PapandreouC., DalianiD., MillikanR.E.Phase I study of intravenous proteasome inhibitor PS-341 in patients with advanced malignancies [Abstract 340].Proc Am Soc Clin Oncol.2001; 20.
7.
HamiltonA.L., EderJ.P., PavlickA.C.PS-341: Phase I study of a novel proteasome inhibitor with pharmacodynamic endpoints [Abstract 336].Proc Am Soc Clin Oncol.2001; 20.
8.
OrlowskiR.Z., StinchcombeT.E., MitchellB.S.Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.J Clin Oncol.2002; 20(22): 4420–7.
FukuokaM., YanoS., GiacconeG.Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer.J Clin Oncol.2003; 21(12): 2237–46.
11.
GiacconeG., JohnsonD.H., ManegoldC.A phase III clinical trial ZD1839 (“Iressa”) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT-1) [abstract 40].Ann Oncol.2002; 13: 2 (suppl 5).
12.
JohnsonD.H., HerbstR., GiacconeG.ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC): Initial results from a phase III trial (INTACT-2) [abstract 4680].Ann Oncol.2002; 13(suppl 1): 127.
13.
CohenE.E.W., RosenF., StadlerW.M.Phase II Trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.J Clin Oncol.2003; 21(10): 1980–7.
14.
Iressa [package literature].Wilmington, DE: AstraZeneca Pharmaceuticals; 2003.
